|
(R)-1-(2-chloroacetyl)pyrrolidine-2-carboxaMide
|
R-1-氯乙?；?2-氰基吡咯烷（維格列汀雜質(zhì)）
|
1211679-98-9
|
|
vildagliptin Impurity Q
|
維格列汀雜質(zhì)Q
|
1803168-08-2
|
|
Vildagliptin Impurity 42
|
維達列汀雜質(zhì)42
|
65732-69-6
|
|
Vildagliptin Impurity 53
|
維格列汀雜質(zhì)53
|
700376-84-7
|
|
1H-Purine-2,6-dione, 7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-8-[(4-methyl-2-quinazolinyl)methoxy]-1-[(4-methyl-2-quinazolinyl)methyl]-
|
利格列汀雜質(zhì)
|
2469626-53-5
|
|
Linagliptin Impurity 28
|
利格列汀雜質(zhì)28
|
2074688-84-7
|
|
Linagliptin impurity 16
|
利拉利汀雜質(zhì)16
|
1955514-80-3
|
|
Linagliptin Impurity 33
|
利格列汀雜質(zhì)33
|
2443735-53-1
|
|
INDEX NAME NOT YET ASSIGNED
|
利格列汀雜質(zhì)
|
2748491-45-2
|
|
Linagliptin Impurity S
|
利格列汀雜質(zhì)S
|
668273-74-3
|
|
2,4,6-Tritertbutylphenol (25 mg) (2,4,6-Tri-tert-butylphenol)
|
|
732-26-3
|
|
2,6-Dichlorophenylacetic Acid
|
|
6575-24-2
|
|
2-Acetylpyridine (1 g)
|
|
1122-62-9
|
|
2,3-Dimethyl-2,3-butanediamine Dihydrochloride (25 mg) (2,3-dimethylbutane-2,3-diamine, hydrochloride)
|
|
75804-28-3
|
|
2,3-Butanedithiol (3 x 1 g)
|
|
4532-64-3
|
|
2'-Fucosyllactose (200 mg)
|
|
41263-94-9
|
|
16Alpha-Hydroxy Prednisolone-9(11)-ene Diacetate (25 mg) (2-((8S,10S,13S,14S,16R,17S)-16-acetoxy-17-hydroxy-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate)
|
|
95943-95-6
|
|
12-Hydroxystearic Acid (200 mg)
|
|
106-14-9
|
|
1-Ethoxy-2-Methylpropane (3 x 0.2 mL)
|
|
627-02-1
|
|
1-Cyclopentyl-4-nitrosopiperazine (CPNP) Solution (1 mL (1 mg/mL)) (1-Cyclopentyl-4-nitrosopiperazine)
|
|
61379-66-6
|
|
1-Benzhydryl-4-nitrosopiperazine Solution (1 mL (1 mg/mL)) (1-benzhydryl-4-nitrosopiperazine)
|
|
1698-25-5
|
|
1-(2-Methoxyphenyl)-4-nitrosopiperazine Solution (1 mL (1 mg/mL)) (1-(2-Methoxyphenyl)-4-nitrosopiperazine)
|
|
2219339-64-5
|
|
1,6-anhydro-D-glucose (50 mg)
|
|
498-07-7
|
|
(+)-Catechin (25 mg)
|
|
154-23-4
|
|
(-)-Epicatechin (50 mg)
|
|
490-46-0
|
|
(1S,2R)-Eliglustat Diastereomer (25 mg) (N-[(1S,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]octanamide)
|
|
1092472-65-5
|
|
(E)-Thiothixene (100 mg)
|
|
3313-27-7
|
|
1,3-Dimethyl-6-nitroindazole (25 mg) (1,3-dimethyl-6-nitro-1H-indazole)
|
|
1354224-47-7
|
|
1,3-Propanediol (1 mL)
|
|
504-63-2
|
|
(R)-1-Boc-3-Aminopiperidine
|
(R)-1-叔丁氧羰基-3-氨基哌啶（利奈唑胺雜質(zhì)）
|
625471-18-3
|
|
INDEX NAME NOT YET ASSIGNED
|
利格列汀雜質(zhì)
|
2748381-67-9
|
|
6'-DesMethyl-6'-Methylhydroxy Etoricoxib
|
依托考昔雜質(zhì)K
|
349536-41-0
|
|
tert-butyl (R)-(1-((4-methylquinazolin-2-yl)methyl)piperidin-3-yl)carbamate
|
利格列汀雜質(zhì)C
|
2514949-81-4
|
|
4-Hydroxyindole (25 mg) (1H-Indol-4-ol)
|
|
2380-94-1
|
|
4-Hydroxyisoleucine (35 mg)
|
|
781658-23-9
|
|
4-Methylacetophenone (1-(4-Methylphenyl)-1-ethanone (4'-Methylacetophenone))
|
|
122-00-9
|
|
4-Phenylbutyl(benzyl)amine hydrochloride (25 mg) (N-benzyl-4-phenylbutan-1-amine, hydrochloride)
|
|
144391-74-2
|
|
3-Acetyl-11-Keto-Beta-Boswellic Acid (20 mg)
|
|
67416-61-9
|
|
3-Amino-2,4,6-triiodobenzoic Acid (50 mg)
|
|
3119-15-1
|
|
6,6'-Dinicotinic Acid (50 mg)
|
|
1802-30-8
|
|
6-Ethylpyrimidine-2,4-diamine (25 mg) (6-Ethylpyrimidine-2,4-diamine)
|
|
514854-12-7
|
|
6-Hydroxynicotinic Acid (50 mg)
|
|
5006-66-6
|
|
6-Methyl-4-phenylchromanol (25 mg) (6-Methyl-4-phenylchroman-2-ol)
|
|
209747-04-6
|
|
6-Methyl-4-phenylchromanone (25 mg) (6-Methyl-4-phenylchroman-2-one)
|
|
40546-94-9
|
|
6-Methylnicotinic Acid (50 mg)
|
|
3222-47-7
|
|
6-O-Methylerythromycin A 9-(O-methyloxime) (25 mg)
|
|
107216-09-1
|
|
6alpha-Hydroxybudesonide (25 mg) ((2S,6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-2,7-Dihydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one)
|
|
577777-51-6
|
|
8-Bromotheophylline (400 mg)
|
|
10381-75-6
|
|
7-Chloromethyl Drospirenone (10 mg)
|
|
932388-90-4
|
|
7-Chloromethyl 17-Epidrospirenone (25 mg)
|
|
932388-89-1
|
|
5-Hydroxy Ivabradine (25 mg) (3-(3-((((S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-5-hydroxy-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one)
|
|
2253977-80-7
|
|
5-Me Bz dC Beta-Cyanoethyl Phosphoramidite (500 mg) (5-Methyl-5'-O-Dimethoxytrityl-N4-benzoyl-2'-deoxycytidine-3'-O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite)
|
|
105931-57-5
|
|
5-O-Methylvisammioside (25 mg)
|
|
84272-85-5
|
|
5-Phenylhydantoin (100 mg)
|
|
89-24-7
|
|
N-Phthalimide-linagliptin
|
N-鄰苯二甲酰亞胺-利格列汀
|
886588-63-2
|
|
Linagliptin impurity KH-2
|
N-(2-乙?；交?-2-(8-溴-7-(丁-2-炔-1-基)-3-甲基-2,6-二氧代-2,3,6,7-四氫-1H--嘌呤-1-基)乙酰胺(利格列汀雜質(zhì))
|
2279114-31-5
|
|
Linagliptin Impurity 29
|
利拉利汀雜質(zhì)29
|
2074688-82-5
|
|
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
|
( 4-(2-羥異丙基)-2-丙基-1H-咪唑-5-甲酸(5-甲基-2-氧雜-1,3-二氧-4-甲基）酯(奧美沙坦酯雜質(zhì))
|
144978-05-2
|
|
Olmesartan Impurity 9
|
奧美沙坦酯雜質(zhì)9
|
849206-42-4
|
|
Olmesartan Medoxomil Impurity 17
|
美沙坦酯雜質(zhì)17
|
1418133-31-9
|
|
Olmesartan Impurity G
|
5-(4-(二溴甲基)-[1,1-二聯(lián)苯]-2-基)-1-三苯甲基-1H-四唑
（奧美沙坦酯雜質(zhì)G）
|
358685-13-9
|
|
Vildagliptin Related Compound A
|
維格列汀雜質(zhì)A
|
741657-02-3
|
|
Vildagliptin Carboxylic Acid Methyl Ester
|
維達列汀羧酸甲酯
|
948574-56-9
|
|
(S)-1-N-CBZ-2-CYANO-PYRROLIDINE
|
(S)-1-N-芐氧羰基-2-氰基吡咯烷（維格列汀雜質(zhì)）
|
63808-36-6
|
|
Vildagliptin Impurity 13
|
維達列汀雜質(zhì)13
|
2577-48-2
|
|
(2S)-1-(2,2,2-trifluoroacetyl)pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-(trifluoroacetyl)-, (S)- (9CI)
|
維格列汀的雜質(zhì)
|
151258-26-3
|
|
Vildagliptin Impurity 57
|
維格列汀雜質(zhì)57
|
913980-23-1
|
|
|
7-木糖基紫杉醇
|
90332-66-4
|
|
|
N,S-（二羧甲基）半胱氨酸
|
907565-13-3
|
|
|
(3R) - 3- 羧基- 5- 氧代- 4- 硫代嗎啉乙酸
|
1601460-92-7
|
|
|
依托咪酯中間體I
|
66512-37-6
|
|
|
依托咪酯雜質(zhì)A
|
3157-27-5
|
|
|
(R,E)-3-羥基-2-(N-(1-苯乙基)甲酰胺基)丙烯酸乙酯
|
1357291-60-1
|
|
|
S-(-)-2-巰基依托咪酯
|
112421-33-7
|
|
|
(R)-1-(1-苯基乙基)-1H-咪唑-5-羧酸甲酯
|
61045-91-8
|
|
2E, 4E-Hexadienoic Acid Isobutylamide (25 mg)
|
|
65937-49-7
|
|
23-EPI-26-Deoxyactein (20 mg)
|
|
501938-01-8
|
|
2-Oxo R-Clopidogrel (10 mg) (methyl (2R)-2-(2-chlorophenyl)-2-(2-oxo-2,6,7,7a-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate)
|
|
1360923-54-1
|
|
2-Oxo Clopidogrel (Mixture of Diastereomers) (10 mg) (methyl 2-(2-chlorophenyl)-2-(2-oxo-2,6,7,7a-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate)
|
|
109904-27-0
|
|
2-Mononitroglycerin (2 ampules x 1 mL)
|
|
620-12-2
|
|
5-Amino-2,4,6-triiodo-N-methylisophthalamic Acid (50 mg)
|
|
2280-89-9
|
|
3-Amino-4-tolylsulfonamide (25 mg) (3-amino-4-methylbenzenesulfonamide)
|
|
6274-28-8
|
|
3-Chloropropiophenone (25 mg) (1-Phenyl-3-chloro-1-propanone)
|
|
936-59-4
|
|
4-Epianhydrotetracycline Hydrochloride (50 mg)
|
|
4465-65-0
|
|
5'-Cytidylic Acid (500 mg)
|
|
63-37-6
|
|
3-Benzyl-4-Heptanone (5 x 0.5 mL)
|
|
7492-37-7
|
|
1H-Imidazole-4-carboxylicacid, 2,3-dihydro-3-(1-phenylethyl)-2-thioxo-, methyl ester
|
|
|
|
Olmesartan Medoxomil Impurity G
|
奧美沙坦MEDOXOMIL雜質(zhì)G
|
761404-82-4
|
|
Acetamide, N-(2-acetylphenyl)-2,2-dichloro-
|
利格列汀雜質(zhì)
|
6140-12-1
|
|
6Beta-Hydroxybudesonide (25 mg) ((2R,6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-2,7-dihydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one)
|
|
88411-77-2
|
|
1,3-Dinitroglycerin (2 ampules x 1 mL)
|
|
623-87-0
|
|
1,2-Dinitroglycerin (2 ampules x 1 mL)
|
|
621-65-8
|
|
4-Hydroxy Duloxetine Acetate (25 mg) ((S)-4-(3-(methylamino)-1-(thiophen-2-yl)propoxy)naphthalen-1-ol, acetate)
|
|
2705426-23-7
|
|
2-Monobromo Aripiprazole Hydrochloride (25 mg) (7-(4-(4-(2-bromophenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one, hydrochloride)
|
|
2748462-55-5
|
|
(2S)-1-(2-chloroacetyl)-N,N-dimethylpyrrolidine-2-carboxamide
|
維格列汀的雜質(zhì)
|
2381862-94-6
|
|
1H-Imidazole-4,5-dicarboxylic acid, 2-propyl-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-
|
奧美沙坦酯雜質(zhì)
|
1350442-05-5
|
|
4-Nitrosopiperazine-1-ethanol Solution (1 mL (1 mg/mL)) (2-(4-Nitrosopiperazin-1-yl)ethan-1-ol)
|
|
48121-20-6
|
|
Olmesartan Medoxomil Impurity O
|
奧美沙坦酯雜質(zhì)O
|
189400-21-3
|
|
4-Nitroso-1-(4-fluorobenzoyl)piperazine Solution (1 mL (1 mg/mL)) ((4-fluorophenyl)(4-nitrosopiperazin-1-yl)methanone)
|
|
2892260-28-3
|
|
6-Keto Fulvestrant (25 mg) ((7Alpha,17Beta)-7-[9-[4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-3,17Beta-dihydroxyestra-1,3,5(10)-trien-6-one; 7Alpha-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-6-one-3,17Beta-diol)
|
|
2858589-78-1
|